MAI Capital Management Has $890,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

According to the latest report filed with the US Securities and Exchange Commission (SEC), MAI Capital Management has increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 17.3% during the first quarter. The investment firm now owns 10,763 shares of the medical research company, an increase of 1,586 shares. As of the most recent SEC filing, the value of MAI Capital Management's holdings in Edwards Lifesciences is estimated to be $890,000.

A few other large investors recently made changes to their holdings of EW. Advisors Asset Management Inc. increased their ownership of Edwards Lifesciences by 0.3% in the first quarter. They now possess 43,556 shares of the medical research company's stock, which is valued at $5,127,000, after obtaining an extra 117 shares during that time frame. Geller Advisors LLC also raised their stake in Edwards Lifesciences by 6.5% during the first quarter. They currently own 1,965 shares of the medical research company's stock, which is valued at $231,000, after acquiring an additional 120 shares. Additionally, Allworth Financial LP increased their holdings in Edwards Lifesciences by 2.5% during the same quarter. They now own 5,015 shares of the medical research company's stock, which is valued at $415,000, after obtaining an extra 122 shares. Rockland Trust Co. also raised their ownership of Edwards Lifesciences by 1.4% in the first quarter. They now possess 8,639 shares of the medical research company's stock, which is valued at $715,000, after purchasing an additional 122 shares. Finally, Financial Architects Inc increased their position in Edwards Lifesciences by 5.1% in the fourth quarter. They now own 2,893 shares of the medical research company's stock, which is valued at $216,000, after purchasing an additional 141 shares during that period. Institutional investors own 79.78% of the stock.

Wall Street Experts Assess

A number of analysts have discussed EW in their reports. Stifel Nicolaus increased their target price on Edwards Lifesciences shares from $75.00 to $87.00 in a research report released on Monday, April 24th. Royal Bank of Canada reaffirmed their "outperform" rating and set a target price of $96.00 on Edwards Lifesciences shares in a research report released on Thursday. Wells Fargo & Company raised their target price on Edwards Lifesciences from $78.00 to $90.00 in a report released on Thursday, April 27th. Jefferies Financial Group raised their price target on Edwards Lifesciences from $103.00 to $107.00 and gave the company a "buy" rating in a research report released on Tuesday, July 25th. Finally, Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 in a research report released on Monday, July 10th. One analyst has rated the stock as a sell, nine have given it a hold rating, and nine have given it a buy rating. According to MarketBeat, the average rating for Edwards Lifesciences is "Hold" and the average price target is $92.68.

Check out our newest inventory analysis for EW

Edwards Lifesciences: Strong Price Performance

The stock of Edwards Lifesciences started the week at a price of $76.58. The company's total value in the market is estimated to be around $46.55 billion. The P/E ratio stands at 33.89, indicating its price relative to earnings. The PEG ratio, which measures the stock's valuation taking into account future growth, is at 4.13. The beta of the stock is 1.02, showing its sensitivity to market fluctuations. Over the past year, Edwards Lifesciences reached a low of $67.13 and a high of $99.40. The company has a low level of debt compared to its equity, with a ratio of 0.09. It also has a strong liquidity position, with a current ratio of 3.15 and a quick ratio of 2.30. These ratios indicate the company's ability to meet its short-term financial obligations. The stock's performance over the past 50 days has been reflected in its fifty-day moving average price of $87.43. Similarly, the 200-day moving average price stands at $84.36, giving an indication of the stock's longer-term trend.

On July 26th, Edwards Lifesciences (NYSE:EW) released its earnings results for the quarter. The medical research company reported earnings per share (EPS) of $0.66, surpassing the estimated $0.65 by $0.01. Edwards Lifesciences had a return on equity of 25.43% and a net profit margin of 24.56%. The company generated $1.53 billion in revenue during the quarter, compared to the expected $1.51 billion. In the same quarter last year, the company earned $0.63 EPS. Overall, the firm's revenue increased by 11.4% compared to the same quarter the previous year. Market analysts predict that Edwards Lifesciences Co. will achieve EPS of 2.55 for the current year.

Bet Like An Insider

In other news, Larry L. Wood, an employee with privileged information, sold 6,421 shares of the company's stock on Monday, August 14th. The shares were sold for an average price of $79.30, resulting in a total transaction value of $509,185.30. After the sale, Wood now owns 213,794 shares in the company, which have an estimated value of $16,953,864.20. This sale was publicly disclosed in a document submitted to the Securities & Exchange Commission, which can be accessed on their official website. In addition to this, Michael A. Mussallem, a board member of Edwards Lifesciences, sold 29,350 shares of the company's stock on Thursday, June 1st. The shares were sold for an average price of $84.46, resulting in a total transaction value of $2,478,901.00. After the sale, Mussallem now directly owns 86,210 shares in the company, with an estimated value of $7,281,296.60. This sale was also disclosed in a document filed with the SEC, available on their website. Furthermore, Larry L. Wood, an employee with privileged information, sold 6,421 shares of the company's stock on Monday, August 14th. The shares were sold for an average price of $79.30, resulting in a total transaction value of $509,185.30. After the sale, Wood now owns 213,794 shares in the company, which have an estimated value of $16,953,864.20. You can find the disclosure for this sale here. Overall, company insiders have sold a total of 159,025 shares of stock, with a market value of $13,629,195, in the past three months. Corporate insiders currently own 1.29% of the company's stock.

Edwards Lifesciences Corporation supplies goods and technologies for the treatment of structural heart ailments, as well as for critical care and surgical monitoring. These offerings are available not only in the United States, but also in Europe, Japan, and various other parts of the world. The company provides products that enable the minimally invasive replacement of heart valves, known as transcatheter heart valve replacement products. Additionally, they offer transcatheter heart valve repair and replacement products specifically designed to address issues with the mitral and tricuspid valves.

Curious about the holdings of other hedge funds on Edwards Lifesciences Co. (NYSE:EW - Free Report)? Head over to HoldingsChannel.com for the most recent 13F filings and insider transactions.

This urgent news update was produced using narrative science technology and financial data from MarketBeat to deliver readers with prompt and precise reporting. MarketBeat's editorial team thoroughly reviewed this article before publishing it. For any inquiries or feedback regarding this news story, please reach out to [email protected].

Invest $1,000 In Edwards Lifesciences Now?

Before you contemplate choosing Edwards Lifesciences, it's important for you to be aware of the following information.

MarketBeat monitors the highest-rated and most successful research analysts on Wall Street, as well as the stocks they suggest to their clients each day. MarketBeat has recognized the five stocks that these exceptional analysts are discreetly advising their clients to purchase before the wider market becomes aware... and unfortunately, Edwards Lifesciences did not make the cut.

Although analysts currently rate Edwards Lifesciences as a "Hold," experts with high ratings suggest that these five stocks are more favorable investment choices.

Check out these five stocks here

Click on the hyperlink provided and we will dispatch MarketBeat's comprehensive manual on investing in cannabis stocks, as well as an analysis of the most promising pot corporations.

Receive this complimentary report